Pangenome profiling of novel drug target against vancomycin-resistant Enterococcus faecium

被引:3
|
作者
Khan, Kanwal [1 ]
Jalal, Khurshid [2 ]
Uddin, Reaz [1 ]
机构
[1] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Lab 103 PCMD Ext, Karachi 75270, Pakistan
[2] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi, Pakistan
来源
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS | 2023年 / 41卷 / 24期
关键词
Pan-genomic analysis; Enterococcus faecium; Traditional Chinese Medicine (TCM) natural products; VRE infections; 3-dehydroquinate dehydrogenase; VIRULENCE DETERMINANTS; HIGH-ACCURACY; DATABASE; DISCOVERY; GENOME; GENES;
D O I
10.1080/07391102.2023.2191134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Enterococcus faecium is a frequent causative agent of nosocomial infection mainly acquired from outgoing hospital patients (Hospital Acquired Infection-HAIs). They are largely involved in the outbreaks of bacteremia, UTI, and endocarditis with a high transmissibility rate. The recent emergence of VRE strain (i.e. vancomycin resistant enterococcus) turned it into high priority pathogen for which new drug research is of dire need. Therefore, in current study, pangenome and resistome analyses were performed for available antibiotic-resistant genomes (n = 216) of E. faecium. It resulted in the prediction of around 5,059 genes as an accessory gene, 1,076 genes as core and 1,558 genes made up a unique genome fraction. Core genes common to all strains were further used for the identification of potent drug targets by applying subtractive genomics approach. Moreover, the COG functional analysis showed that these genomes are highly enriched in metabolic pathways such as in translational, ribosomal, proteins, carbohydrates and nucleotide transport metabolism. Through subtractive genomics it was observed that 431 proteins were non-homologous to the human proteome, 166 identified as essential for pathogen survival while 26 as potential and unique therapeutic targets. Finally, 3-dehydroquinate dehydrogenase was proposed as a potent drug target for further therapeutic candidate identification. Moreover, the molecular docking and dynamic simulation technique were applied to performed a virtual screening of natural product libraries (i.e., TCM and Ayurvedic compounds) along with 3-amino-4,5-dihydroxy-cyclohex-1-enecarboxylate (DHS) as a standard compound to validate the study. Consequently, Argeloside I, Apigenin-7-O-gentiobioside (from Ayurvedic library), ZINC85571062, and ZINC85570908 (TCM library) compounds were identified as potential inhibitors of 3-dehydroquinate dehydrogenase. The study proposed new compounds as novel therapeutics, however, further experimental validation is needed as a follow-up.Communicated by Ramaswamy H. Sarma
引用
收藏
页码:15647 / 15660
页数:14
相关论文
共 50 条
  • [21] Biological characteristics and anti-biofilm activity of a lytic phage against vancomycin-resistant Enterococcus faecium
    Goodarzi, Forough
    Hallajzadeh, Masoumeh
    Sholeh, Mohammad
    Talebi, Malihe
    Mahabadi, Vahid Pirhajati
    Amirmozafari, Nour
    IRANIAN JOURNAL OF MICROBIOLOGY, 2021, 13 (05) : 691 - 702
  • [22] Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium
    Gargvanshi, Shivani
    Gutheil, William G.
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [23] Emergence of vancomycin-resistant Enterococcus faecium in Sfax:: clinical features and molecular typing
    Abbassi, M. S.
    Znazen, A.
    Mahjoubi, F.
    Hammami, A.
    Ben Hassen, A.
    MEDECINE ET MALADIES INFECTIEUSES, 2007, 37 (04): : 240 - 241
  • [24] Clonal heterogeneity of clinical isolates of vancomycin-resistant Enterococcus faecium with unique vanS
    Pourshafie, Mohammad R.
    Talebi, Malihe
    Saifi, Mahnaz
    Katouli, Mohammad
    Eshraghi, Saeed
    Kuehn, Inger
    Moellby, Roland
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (05) : 722 - 727
  • [25] Nosocomial outbreak of vancomycin-resistant Enterococcus faecium at a German University Pediatric Hospital
    Elsner, HA
    Sobottka, I
    Feucht, HH
    Harps, E
    Haun, C
    Mack, D
    Ganschow, R
    Laufs, R
    Kaulfers, PM
    INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH, 2000, 203 (02) : 147 - 152
  • [26] Epidemiological profiles and pathogenicity of Vancomycin-resistant Enterococcus faecium clinical isolates in Taiwan
    Lin, Pei-Yun
    Chan, Shang-Yih
    Stern, Arnold
    Chen, Po -Hsiang
    Yang, Hung -Chi
    PEERJ, 2023, 11
  • [27] Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children
    Gray, JW
    Darbyshire, PJ
    Beath, SV
    Kelly, D
    Mann, JR
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 234 - 238
  • [28] NEOMYCIN BLOOD AGAR AS A SELECTIVE MEDIUM FOR VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM
    CHADWICK, PR
    OPPENHEIM, BA
    JOURNAL OF CLINICAL PATHOLOGY, 1995, 48 (11) : 1068 - 1070
  • [29] Real-time PCR surveillance of vanA for vancomycin-resistant Enterococcus faecium
    Kim, Taek Soo
    Kwon, Hye Lin
    Song, Sang Hoon
    Song, Kyoung-Ho
    Kim, Hong Bin
    Park, Kyoung Un
    Song, Junghan
    Kim, Eui-Chong
    MOLECULAR MEDICINE REPORTS, 2012, 6 (03) : 488 - 492
  • [30] Management of vancomycin-resistant Enterococcus faecium in Dutch healthcare institutes: a nationwide survey
    Mulder, M.
    Vendrik, K. E. W.
    van Kessel, S. A. M.
    Notermans, D. W.
    Schoffelen, A. F.
    Flipse, J.
    Hendrickx, A. P. A.
    van der Zwet, W. C.
    Schneeberge-van der Linden, C.
    JOURNAL OF HOSPITAL INFECTION, 2025, 155 : 51 - 59